Earlier filters for better programs

ADMET and Developability

BioForge treats developability as a first-class discovery constraint. For small molecules and biologics, the platform helps teams reason over ADMET predictions, assay evidence, liabilities, off-target risks, formulation considerations, and modality-specific developability issues before programs become expensive to redirect.

Surface ADMET and developability liabilities while designs are still flexible.

Compare property tradeoffs across molecules, peptides, binders, and antibodies.

Tie risk flags to concrete next assays and mitigation experiments.

Problem context

Why this problem matters

Late failure cost

Programs often fail after substantial chemistry or biologics effort because risk signals were visible but not integrated early enough.

Tradeoff management

Potency, exposure, selectivity, solubility, stability, immunogenicity, and manufacturability need to be balanced rather than optimized in isolation.

Decision clarity

Teams need a ranked view of what to advance, what to fix, and what to stop before validation capacity is committed.